Insitro was founded in 2018 by Daphne Koller. The company has not publicly endorsed plans to participate in an IPO.
Insitro is an AI-powered drug development company. Board member Dr. Roger Perlmutter describes the three pillars of the company's approach as, "Target identification, lead discovery, and the elaboration of highly evolved therapeutic candidates." Insitro has raised more than $600 million in venture capital funding from investors including CPP Investments, Andreessen Horowitz, T. Rowe Price Associates, Casdin Capital, Temasek, and Softbank Investment Advisors. The company did not disclose valuation figures following a $400 million Series C fundraising round in 2021.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/15/2021 | Series C | $400MM | $xx.xx | $256.53B | Alexandria Venture Investments, Andreessen Horowitz, Arch Venture Partners, Blackrock, Casdin Capital, Cpp Investments, Foresite Capital, Gv, Hof Capital, Softbank, Temasek, Third Rock Ventures, T. Rowe Price, Two Sigma Ventures | |
Price per Share
$xx.xx
Shares Outstanding
21,868,541
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Andreessen Horowitz, Arch Venture Partners, Blackrock, Casdin Capital, Cpp Investments, Foresite Capital, Gv, Hof Capital, Softbank, Temasek, Third Rock Ventures, T. Rowe Price, Two Sigma Ventures
|
||||||
05/26/2020 | Series B | $149.22MM | $xx.xx | $72.5B | Alexandria Venture Investments, Andreessen Horowitz, Arch Venture Partners, Blackrock, Casdin Capital, Cpp Investments, Foresite Capital, Gv, Hof Capital, Third Rock Ventures, T. Rowe Price, Two Sigma Ventures, Wuxi Apptec | |
Price per Share
$xx.xx
Shares Outstanding
23,949,729
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Andreessen Horowitz, Arch Venture Partners, Blackrock, Casdin Capital, Cpp Investments, Foresite Capital, Gv, Hof Capital, Third Rock Ventures, T. Rowe Price, Two Sigma Ventures, Wuxi Apptec
|
||||||
05/01/2018 | Series A-1 | $30MM | $xx.xx | $30.91B | A16z, Alexandria Venture, Arch Venture, Bezos Expeditions, Foresite Capital, Gv, Mubadala Investment Company, Third Rock Ventures, Two Sigma Ventures, Verily | |
Price per Share
$xx.xx
Shares Outstanding
33,327,366
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
A16z, Alexandria Venture, Arch Venture, Bezos Expeditions, Foresite Capital, Gv, Mubadala Investment Company, Third Rock Ventures, Two Sigma Ventures, Verily
|
||||||
05/01/2018 | Series A-2 | $49.41MM | $xx.xx | $30.91B | A16z, Alexandria Venture, Arch Venture, Bezos Expeditions, Foresite Capital, Gv, Mubadala Investment Company, Third Rock Ventures, Two Sigma Ventures, Verily | |
Price per Share
$xx.xx
Shares Outstanding
18,359,806
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
A16z, Alexandria Venture, Arch Venture, Bezos Expeditions, Foresite Capital, Gv, Mubadala Investment Company, Third Rock Ventures, Two Sigma Ventures, Verily
|